July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Eric K. Singhi: U.S. FDA Approved Taletrectinib for ROS1+ mNSCLC
Jun 12, 2025, 19:16

Eric K. Singhi: U.S. FDA Approved Taletrectinib for ROS1+ mNSCLC

Eric K. Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post on X:

“U.S. FDA approves taletrectinib for ROS1+ mNSCLC.
Treatment-naïve:
– ORR: 90% (TRUST-I), 85% (TRUST-II)
– DOR ≥12 mo: 72%, 63%
TKI-pretreated:
– ORR: 52% (TRUST-I), 62% (TRUST-II)
– DOR ≥6 mo: 74%, 83%
Liver tox, ILD/pneumonitis, QTc, hyperuricemia, myalgia, fractures.”

Eric K. Singhi

More posts featuring Eric Singhi on OncoDaily.